Novartis’s Gilenya Given Final Approval by U.K.’s Cost Agency

Novartis AG (NOVN)’s multiple sclerosis pill Gilenya won final approval from England’s health-cost agency for some patients after the company agreed to a discounted price.

The National Institute for Health and Clinical Excellence, or NICE, recommended Gilenya as a treatment option for some adults with relapsing-remitting multiple sclerosis, a form of the disease in which symptoms worsen and improve periodically, it said in a statement today. The decision confirms a preliminary ruling made last month.

Gilenya costs about 19,196 pounds ($30,970). NICE isn’t disclosing the size of the discount that Novartis offered.

To contact the reporter on this story: Phil Serafino in Paris at

To contact the editor responsible for this story: Phil Serafino at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.